JS-K, a diazeniumdiolate-based nitric oxide (NO)-releasing prodrug, is currently in late pre-clinical development as an anti-cancer drug candidate. This prodrug was designed to be activated by glutathione (GSH) to release NO. To increase the potency of JS-K, we are investigating the effect of slowing the reaction of the prodrugs with GSH. Herein, we report the effect of replacement of nitro group(s) by other electron-withdrawing group(s) in JS-K and its homo-piperazine analogues on GSH activation and the drugs' biological activity. We show that nitro-to-cyano substitution increases the half-life of the prodrug in the presence of GSH without compromising the compound's in vivo antitumor activity.
JS-K, a diazeniumdiolate-based n class="Chemical">nitric oxide (NO)-releasing prodrug, is currently in late pre-clinical development as an anti-cancer drug candidate. This prodrug was designed to be activated by glutathione (GSH) to release NO. To increase the potency of JS-K, we are investigating the effect of slowing the reaction of the prodrugs with GSH. Herein, we report the effect of replacement ofnitro group(s) by other electron-withdrawing group(s) in JS-K and its homo-piperazine analogues on GSH activation and the drugs' biological activity. We show that nitro-to-cyano substitution increases the half-life of the prodrug in the presence ofGSH without compromising the compound's in vivo antitumor activity.
Authors: Anna E Maciag; Rahul S Nandurdikar; Sam Y Hong; Harinath Chakrapani; Bhalchandra Diwan; Nicole L Morris; Paul J Shami; Yih-Horng Shiao; Lucy M Anderson; Larry K Keefer; Joseph E Saavedra Journal: J Med Chem Date: 2011-10-28 Impact factor: 7.446
Authors: Paul J Shami; Joseph E Saavedra; Challice L Bonifant; Jingxi Chu; Vidya Udupi; Swati Malaviya; Brian I Carr; Siddhartha Kar; Meifeng Wang; Lee Jia; Xinhua Ji; Larry K Keefer Journal: J Med Chem Date: 2006-07-13 Impact factor: 7.446
Authors: Paul J Shami; Joseph E Saavedra; Lai Y Wang; Challice L Bonifant; Bhalchandra A Diwan; Shivendra V Singh; Yijun Gu; Stephen D Fox; Gregory S Buzard; Michael L Citro; David J Waterhouse; Keith M Davies; Xinhua Ji; Larry K Keefer Journal: Mol Cancer Ther Date: 2003-04 Impact factor: 6.261
Authors: Tanyel Kiziltepe; Teru Hideshima; Kenji Ishitsuka; Enrique M Ocio; Noopur Raje; Laurence Catley; Chun-Qi Li; Laura J Trudel; Hiroshi Yasui; Sonia Vallet; Jeffery L Kutok; Dharminder Chauhan; Constantine S Mitsiades; Joseph E Saavedra; Gerald N Wogan; Larry K Keefer; Paul J Shami; Kenneth C Anderson Journal: Blood Date: 2007-03-23 Impact factor: 22.113
Authors: Anna E Maciag; Harinath Chakrapani; Joseph E Saavedra; Nicole L Morris; Ryan J Holland; Ken M Kosak; Paul J Shami; Lucy M Anderson; Larry K Keefer Journal: J Pharmacol Exp Ther Date: 2010-10-20 Impact factor: 4.030
Authors: Harinath Chakrapani; Ravi C Kalathur; Anna E Maciag; Michael L Citro; Xinhua Ji; Larry K Keefer; Joseph E Saavedra Journal: Bioorg Med Chem Date: 2008-09-30 Impact factor: 3.641
Authors: Rahul S Nandurdikar; Anna E Maciag; Michael L Citro; Paul J Shami; Larry K Keefer; Joseph E Saavedra; Harinath Chakrapani Journal: Bioorg Med Chem Lett Date: 2009-03-28 Impact factor: 2.823
Authors: Marike W van Gisbergen; Marcus Cebula; Jie Zhang; Astrid Ottosson-Wadlund; Ludwig Dubois; Philippe Lambin; Kenneth D Tew; Danyelle M Townsend; Guido R M M Haenen; Marie-José Drittij-Reijnders; Hisao Saneyoshi; Mika Araki; Yuko Shishido; Yoshihiro Ito; Elias S J Arnér; Hiroshi Abe; Ralf Morgenstern; Katarina Johansson Journal: Mol Pharm Date: 2016-04-28 Impact factor: 4.939
Authors: Anna E Maciag; Ryan J Holland; Y-S Robert Cheng; Luis G Rodriguez; Joseph E Saavedra; Lucy M Anderson; Larry K Keefer Journal: Redox Biol Date: 2013-02-01 Impact factor: 11.799
Authors: Anna E Maciag; Ryan J Holland; Youseung Kim; Vandana Kumari; Christina E Luthers; Waheed S Sehareen; Debanjan Biswas; Nicole L Morris; Xinhua Ji; Lucy M Anderson; Joseph E Saavedra; Larry K Keefer Journal: J Med Chem Date: 2014-02-25 Impact factor: 7.446